Antibody therapy for COVID-19 shows promise in animal tests: NHRI

A monoclonal antibody (mAb) treatment being developed by Taiwan's National Health Research Institutes (NHRI) has been shown to significantly reduce levels of the COVID-19 coronavirus in infected animals, the body's leading infectious disease official said Wednesday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)